Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponesimod Extension in RRMS
NCT01093326Phase 2Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- May 2010
- Primary completion
- Sep 2023
- Modality
- Covalent Small Molecules, Molecular Glues, Classical Binding Small Molecules
- Countries
- 20
01
Overview
Phase 2, randomised, double-blind trial of ponesimod in relapsing-remitting multiple sclerosis (RRMS) (3 arms), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoints: Annualized Relapse Rate of Confirmed Relapses up to 13.3 years, Time to First Confirmed Relapse up to 13.3 years and 1 more. Started May 2010; status: completed.
02
Drugs
ponesimod
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT01093326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01093326.